Welcome to our dedicated page for QT Imaging Holdings news (Ticker: QTIH), a resource for investors and traders seeking the latest updates and insights on QT Imaging Holdings stock.
QT Imaging Holdings, Inc. (OTCQB: QTIH) is a medical device company focused on body imaging systems that use low frequency sound waves, with a particular emphasis on breast imaging. The company’s news flow centers on the commercialization of its QTI Breast Acoustic CT™ scanner, a breast imaging system described as radiation-free, contrast-free, and compression-free, as well as on the evolution of its cloud-enabled imaging platform.
On this page, readers can follow company announcements about scanner shipments and revenue milestones, including updates that link revenue growth to the number of QTI Breast Acoustic CT™ scanners shipped. QT Imaging’s press releases also provide details on distribution agreements with partners such as NXC Imaging, Inc., a subsidiary of Canon Medical Systems USA, and Gulf Medical Co. in Saudi Arabia, which are referenced in connection with shipment plans and revenue outlooks.
Investors and healthcare professionals can review financial result announcements, where QT Imaging discusses quarterly revenue, year-over-year growth, and non-GAAP measures such as EBITDA and Adjusted EBITDA, along with commentary on its financial position and capital structure. News items also cover capital markets activities, including a private placement (PIPE) financing and a 3:1 reverse stock split, as well as the company’s stated intention to pursue a relisting on the Nasdaq Capital Market.
Beyond financial and corporate updates, QT Imaging issues news about technology collaborations and clinical outreach. Examples include a strategic collaboration with Intelerad Medical Systems to deploy cloud-based PACS across its research and commercial networks, and participation in the RSNA annual meeting with seminars on quantitative transmission imaging and live demonstrations of its FDA-cleared Breast Acoustic CT™ scanner. Visitors can use this news feed to track how QT Imaging is advancing its imaging technology, expanding distribution, and developing its cloud SaaS and AI/ML capabilities over time.
QT Imaging Holdings (OTCQB:QTIH) has released version 4.4.0 of its image reconstruction software for the FDA-cleared QTscan™ Breast Acoustic CT™ scanner. The update, powered by NVIDIA's L40 GPU with Ada Lovelace architecture, significantly reduces image processing time while maintaining diagnostic accuracy and image quality comparable to MRI.
The QTscan™ technology provides non-invasive 3D breast imaging without compression, contrast agents, or ionizing radiation. The software update ensures minimal downtime and seamless workflow integration, enhancing scalability for breast imaging centers with increasing patient volumes. The company continues to develop machine learning algorithms to improve both processing and scanning times.
QT Imaging Holdings (OTCQB:QTIH) has successfully delivered and installed its QT Imaging Breast Acoustic CT™ Scanner at Innovative Radiology in Des Moines, Iowa, marking the first installation of this technology in the state. The scanner utilizes proprietary low-frequency ultrasound technology to create high-resolution, 3D breast images without using ionizing radiation or compression, making it particularly beneficial for patients with dense breast tissue.
Led by Dr. John Tentinger, Innovative Radiology becomes the first facility in Iowa to offer this advanced imaging solution alongside their existing suite of diagnostic technologies, including mammography, MRI, CT, ultrasound, and X-ray. The installation represents a significant step in expanding access to radiation-free breast imaging technology in the region.
QT Imaging Holdings (OTCQB:QTIH), a medical device company focused on body imaging systems, has secured a $200,000 PIPE investment from Mr. Leon Recanati, vice chairman of Israel Cancer Association. The investment terms include the purchase of 205,339 unregistered common stock shares at $0.974 per share, representing a 10% premium to the 5-day VWAP as of May 9, 2025. The deal also includes 205,339 warrants with an exercise price of $1.12 per share.
The transaction, expected to close by May 19, 2025, was placed directly by the company without banking fees. The proceeds will be used as working capital to support business growth.
QT Imaging Holdings (OTCQB:QTIH) has secured a $500,000 PIPE investment from company insiders. Board Chairman Dr. Avi Katz and CEO Dr. Raluca Dinu have agreed to purchase 784,929 unregistered common stock shares at $0.637 per share, representing a 10% premium to the volume weighted average trading price on April 9, 2025.
The deal includes 1,569,858 warrants with an exercise price of $0.72 per share. The financing, expected to close by April 24, 2025, was placed directly by QTI without banking fees. The proceeds will be used as working capital to support the company's business growth.
QT Imaging Holdings (OTCQB:QTIH) has secured a $500,000 PIPE investment from company insiders. The investment comes from Board Chairman Dr. Avi Katz and CEO Dr. Raluca Dinu, who agreed to purchase 784,929 unregistered common stock shares at $0.637 per share on April 9, 2025.
The deal includes 1,569,858 warrants with an exercise price of $0.72 per share. The share price represents a 10% premium to the company's volume weighted average trading price. The financing, expected to close by April 24, 2025, was placed directly by QTI without banking fees. The proceeds will be used as working capital to support the company's business growth.
QT Imaging Holdings (OTCQB:QTIH) has announced its participation in the 2025 SBI Breast Imaging Symposium, scheduled for April 24-27 in Colorado Springs, Colorado. The company will showcase its innovative QT Breast Acoustic CT™ imaging technology at Canon Medical Systems' booth 535.
The technology represents a significant advancement in breast imaging, offering radiation-free and highly accurate breast scans. It is specifically designed to improve early detection of breast abnormalities and enhance patient outcomes, with particular effectiveness for women with dense breast tissue.
Dr. Bilal Malik, Chief Science Officer, emphasized the company's commitment to engaging with healthcare professionals and demonstrating how their technology aims to transform breast imaging practices globally. The company maintains its focus on advancing women's healthcare through innovative technologies and strategic partnerships.
QT Imaging Holdings (OTCQB:QTIH) has announced the successful shipment of six QT Breast Acoustic CT™ Systems in Q1 2025, generating total revenue of $2.7 million. The company met its previously projected targets, marking a significant milestone in its commercial expansion.
The achievement underscores the success of QTIH's strategic partnership with NXC Imaging, Inc. and reinforces their position in the breast imaging market. The company aims to continue advancing its product offerings and expanding its presence in the medical imaging industry.
QT Imaging Holdings (OTCQB: QTIH) reported its Q4 and full-year 2024 financial results, highlighting significant growth with revenue of $4.9 million from twelve QT Breast Acoustic CT Scanner shipments, achieving a 54% gross margin. The company secured key financial arrangements, including a $2.56 million PIPE investment from board members and a $10.1 million Lynrock Lake Term Loan.
Q4 2024 showed commercial revenue of $0.8 million with a 47% gross margin, though net loss was $3.5 million. The company cleared all short-term debt liabilities and established strategic partnerships with NXC Imaging for US distribution and Canon Medical Systems for manufacturing.
Looking ahead, QT Imaging projects strong revenue growth, forecasting $18 million for 2025 (40 scanners) and $27 million for 2026 (60 scanners), supported by minimum order quantities in their amended distribution agreement with NXC Imaging.
QT Imaging Holdings (OTCQB:QTIH), a medical device company focused on innovative body imaging systems, has successfully completed its uplisting to the OTCQB Venture Market. The company's stock began trading on the OTCQB on Tuesday, March 11, following approval from OTC Markets Group Inc. This strategic move is expected to enhance the company's market value, visibility, and transparency.